<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675998</url>
  </required_header>
  <id_info>
    <org_study_id>TEN-02-201</org_study_id>
    <nct_id>NCT02675998</nct_id>
  </id_info>
  <brief_title>An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)</brief_title>
  <official_title>An 8-week, Multicenter, Randomized, Double-Blind, Parallel Group Study With a 4-week, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Efficacy, Safety, and Tolerability of Tenapanor to Treat Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardelyx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardelyx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 3, 8-week, randomized, double-blind, parallel group, multi-center study with a&#xD;
      4-week, placebo-controlled, randomized withdrawal period will evaluate the efficacy, safety&#xD;
      and tolerability of Tenapanor to treat hyperphosphatemia in end-stage renal disease patients&#xD;
      on hemodialysis (ESRD-HD). Subjects who qualify are randomized into the study will either&#xD;
      receive 3 mg BID, 10 mg BID, or a titration regimen of tenapanor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of a screening visit, a wash out period of up to 3 weeks, when existing&#xD;
      phosphate lowering medication is withheld, an 8-week treatment period, in which all groups&#xD;
      receive tenapanor, and a 4-week placebo-controlled, randomized withdrawal period, during&#xD;
      which patients are re-randomized 1:1 to either remain on their current tenapanor treatment or&#xD;
      placebo.&#xD;
&#xD;
      Depending on the increase in serum phosphate levels, subjects can be randomized 1,2, or 3&#xD;
      weeks after being taken off their phosphate lowering medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">January 17, 2018</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Placebo Adjusted Change in Serum Phosphate During Randomized Withdrawal Period From Pooled Tenapanor Arms</measure>
    <time_frame>4 weeks</time_frame>
    <description>Serum phosphorus difference between placebo and tenapanor in the change from the end of the 8 week treatment period to the end of the randomized withdrawal period in Efficacy Analysis Set. The efficacy analysis was pre-defined to be a pooled analysis of all tenapanor treated patients with a minimum of a 1.2 mg/dL decrease in serum phosphorus during the 8-week treatment period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Phosphate During 8-Week Treatment Period</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Serum phosphorus difference between baseline (end of washout period) to the end of the 8 week treatment period in ITT analysis set</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Hyperphosphatemia</condition>
  <arm_group>
    <arm_group_label>3mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenapanor, 3mg BID (6mg total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenapanor, 10mg BID (20mg total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Titration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenapanor, patients start at 30mg BID and can down titrate weekly to 20, 15, 10, and 3mg BID, sequentially based on a GI tolerability question</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenapanor</intervention_name>
    <arm_group_label>10mg BID</arm_group_label>
    <arm_group_label>3mg BID</arm_group_label>
    <arm_group_label>Dose Titration</arm_group_label>
    <other_name>RDX5791, AZD1722</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 80 years old&#xD;
&#xD;
          -  Females must be non-pregnant, non-lactating, and either be post-menopausal for at&#xD;
             least 12 months, have documentation of irreversible surgical sterilization, or confirm&#xD;
             the use of one of the acceptable contraceptive methods.&#xD;
&#xD;
          -  Males must agree to avoid fathering a child and agree to use an appropriate method of&#xD;
             contraception&#xD;
&#xD;
          -  Chronic maintenance hemodialysis 3x/week for at least 3 months&#xD;
&#xD;
          -  Kt/V ≥ 1.3 at most recent measurement prior to screening&#xD;
&#xD;
          -  Prescribed and taking at least 3 doses of phosphate binder per day&#xD;
&#xD;
          -  Serum phosphate levels should be between 4.0 and 7.0 mg/dL (inclusive) at screening&#xD;
&#xD;
          -  For randomization in the study, after 1 week wash-out of phosphate binders, subjects&#xD;
             must have serum phosphate level of at least 9 mg/dL but below 10 mg/dL and have had an&#xD;
             increase of at least 1.5 mg/dL versus pre-wash out value&#xD;
&#xD;
          -  For randomization in the study, after 2 or 3 weeks wash-out of phosphate binders,&#xD;
             subjects must have serum phosphate level of at least 6 mg/dL but below 10 mg/dL and&#xD;
             have had an increase of at least 1.5 mg/dL versus pre-wash out value&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe hyperphosphatemia defined as &gt;10 mg/dL on Phosphate-binders at any time point&#xD;
             during clinical routine monitoring for the 3 preceding months before screening&#xD;
&#xD;
          -  Serum parathyroid hormone &gt;1200 pg/mL&#xD;
&#xD;
          -  Persistent metabolic acidosis defined as serum carbon dioxide &lt;18 mmol/L from two&#xD;
             consecutive measurements during screening and washout periods&#xD;
&#xD;
          -  Clinical signs of hypovolemia at randomization&#xD;
&#xD;
          -  History of inflammatory bowel disease (IBD) or diarrhea predominant irritable bowel&#xD;
             syndrome (IBS-D)&#xD;
&#xD;
          -  Scheduled for living donor kidney transplant, change to peritoneal dialysis, home HD&#xD;
             or plans to relocate to another center during the study period&#xD;
&#xD;
          -  Diarrhea or loose stools during the week before randomization defined as BSFS ≥ 6 and&#xD;
             frequency ≥ 3 for 2 or more days&#xD;
&#xD;
          -  Any evidence of or treatment of malignancy within one year, excluding non-melanomatous&#xD;
             malignancies of the skin&#xD;
&#xD;
          -  Positive serology with evidence of significant hepatic impairment or WBC elevation&#xD;
             according to the Investigator&#xD;
&#xD;
          -  Life expectancy &lt; 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David P Rosenbaum, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Ardelyx, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 429</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 425</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Clinical Site 403</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 410</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33313</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 430</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 427</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 432</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 415</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 402</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 424</name>
      <address>
        <city>Roseville</city>
        <state>Michigan</state>
        <zip>48066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 409</name>
      <address>
        <city>Brookhaven</city>
        <state>Mississippi</state>
        <zip>39601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 417</name>
      <address>
        <city>Columbus</city>
        <state>Mississippi</state>
        <zip>39705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 431</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 423</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 416</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 419</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 408</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 411</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 420</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 426</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 412</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 414</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 404</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 421</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 428</name>
      <address>
        <city>Sumter</city>
        <state>South Carolina</state>
        <zip>29150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 413</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37923</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 418</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 406</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 405</name>
      <address>
        <city>Bellville</city>
        <state>Texas</state>
        <zip>77418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 422</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 407</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardelyx Investigative Site 401</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <results_first_submitted>May 9, 2020</results_first_submitted>
  <results_first_submitted_qc>August 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 10, 2020</results_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>3mg BID</title>
          <description>Tenapanor, 3mg BID (6mg total)&#xD;
Tenapanor</description>
        </group>
        <group group_id="P2">
          <title>10mg BID</title>
          <description>Tenapanor, 10mg BID (20mg total)&#xD;
Tenapanor</description>
        </group>
        <group group_id="P3">
          <title>30 mg Dose Titration</title>
          <description>Tenapanor, patients start at 30mg BID and can down titrate weekly to 20, 15, 10, and 3mg BID, sequentially based on a GI tolerability question&#xD;
Tenapanor</description>
        </group>
        <group group_id="P4">
          <title>Randomized Withdrawal Period Placebo</title>
          <description>These were participants re-randomized to placebo during the 4-week withdrawal period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>8-Week Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="72"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>GI side Effects</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>4-Week Randomized Withdrawal Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This was a placebo-controlled randomized withdrawal study. All participants received drug during the first 8-weeks (no placebo) and then were randomized 1:1 to either remain on tenapanor dose or receive placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>3mg BID</title>
          <description>Tenapanor, 3mg BID (6mg total)</description>
        </group>
        <group group_id="B2">
          <title>10mg BID</title>
          <description>Tenapanor, 10mg BID (20mg total)</description>
        </group>
        <group group_id="B3">
          <title>Dose Titration</title>
          <description>Tenapanor, patients start at 30mg BID and can down titrate weekly to 20, 15, 10, and 3mg BID, sequentially based on a GI tolerability question</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo&#xD;
Placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="74"/>
            <count group_id="B2" value="73"/>
            <count group_id="B3" value="72"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="219"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.7" spread="11.49"/>
                    <measurement group_id="B2" value="57.4" spread="10.81"/>
                    <measurement group_id="B3" value="54.2" spread="10.87"/>
                    <measurement group_id="B5" value="55.8" spread="11.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B5" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B5" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B5" value="179"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B5" value="125"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B5" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>m/kg^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.5" spread="8.52"/>
                    <measurement group_id="B2" value="33.6" spread="8.50"/>
                    <measurement group_id="B3" value="33.4" spread="8.15"/>
                    <measurement group_id="B5" value="33.1" spread="8.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Placebo Adjusted Change in Serum Phosphate During Randomized Withdrawal Period From Pooled Tenapanor Arms</title>
        <description>Serum phosphorus difference between placebo and tenapanor in the change from the end of the 8 week treatment period to the end of the randomized withdrawal period in Efficacy Analysis Set. The efficacy analysis was pre-defined to be a pooled analysis of all tenapanor treated patients with a minimum of a 1.2 mg/dL decrease in serum phosphorus during the 8-week treatment period</description>
        <time_frame>4 weeks</time_frame>
        <population>Patients who completed the first 8-weeks and had a minimum of a 1.2 mg/dL decrease in serum phosphorus were included in the analysis. Also, it was a pre-specificied pooled analysis where all the tenapanor treated patients were combined thus all patients are included in the 30 mg dose titration group.</population>
        <group_list>
          <group group_id="O1">
            <title>3mg BID</title>
            <description>Tenapanor, 3mg BID (6mg total)&#xD;
Tenapanor</description>
          </group>
          <group group_id="O2">
            <title>10mg BID</title>
            <description>Tenapanor, 10mg BID (20mg total)&#xD;
Tenapanor</description>
          </group>
          <group group_id="O3">
            <title>30 mg Dose Titration</title>
            <description>Tenapanor, patients start at 30mg BID and can down titrate weekly to 20, 15, 10, and 3mg BID, sequentially based on a GI tolerability question&#xD;
Tenapanor</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Placebo Adjusted Change in Serum Phosphate During Randomized Withdrawal Period From Pooled Tenapanor Arms</title>
          <description>Serum phosphorus difference between placebo and tenapanor in the change from the end of the 8 week treatment period to the end of the randomized withdrawal period in Efficacy Analysis Set. The efficacy analysis was pre-defined to be a pooled analysis of all tenapanor treated patients with a minimum of a 1.2 mg/dL decrease in serum phosphorus during the 8-week treatment period</description>
          <population>Patients who completed the first 8-weeks and had a minimum of a 1.2 mg/dL decrease in serum phosphorus were included in the analysis. Also, it was a pre-specificied pooled analysis where all the tenapanor treated patients were combined thus all patients are included in the 30 mg dose titration group.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1.4" spread="0.23"/>
                    <measurement group_id="O4" value="0.6" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Phosphate During 8-Week Treatment Period</title>
        <description>Serum phosphorus difference between baseline (end of washout period) to the end of the 8 week treatment period in ITT analysis set</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>There was no placebo group during the 8-week treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>3mg BID</title>
            <description>Tenapanor, 3mg BID (6mg total)&#xD;
Tenapanor</description>
          </group>
          <group group_id="O2">
            <title>10mg BID</title>
            <description>Tenapanor, 10mg BID (20mg total)&#xD;
Tenapanor</description>
          </group>
          <group group_id="O3">
            <title>30 mg Dose Titration</title>
            <description>Tenapanor, patients start at 30mg BID and can down titrate weekly to 20, 15, 10, and 3mg BID, sequentially based on a GI tolerability question&#xD;
Tenapanor</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Phosphate During 8-Week Treatment Period</title>
          <description>Serum phosphorus difference between baseline (end of washout period) to the end of the 8 week treatment period in ITT analysis set</description>
          <population>There was no placebo group during the 8-week treatment period.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.17"/>
                    <measurement group_id="O2" value="-1.1" spread="0.17"/>
                    <measurement group_id="O3" value="-1.1" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks. The first 8 weeks were tenapanor only and during the last 4 weeks half of the tenapanor-treated patients from the first 8 weeks were randomized to receive placebo</time_frame>
      <desc>There was no placebo during the first 8-weeks</desc>
      <group_list>
        <group group_id="E1">
          <title>3mg BID</title>
          <description>Tenapanor, 3mg BID (6mg total)</description>
        </group>
        <group group_id="E2">
          <title>10mg BID</title>
          <description>Tenapanor, 10mg BID (20mg total)</description>
        </group>
        <group group_id="E3">
          <title>30 mg Dose Titration</title>
          <description>Tenapanor, patients start at 30mg BID and can down titrate weekly to 20, 15, 10, and 3mg BID, sequentially based on a GI tolerability question</description>
        </group>
        <group group_id="E4">
          <title>Randomized Withdrawal Period Placebo</title>
          <description>The 164 patients that ended the 8 week treatment period were re-randomized 1:1 to stay on tenapanor or receive placebo. The patients in this group were re-randomized to receive placebo for the last 4 weeks of the study</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="74"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="73"/>
                <counts group_id="E3" events="34" subjects_affected="34" subjects_at_risk="72"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Development Officer</name_or_title>
      <organization>Ardelyx</organization>
      <phone>6175134929</phone>
      <email>drosenbaum@ardelyx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

